David A. Boothman

17.0k total citations · 3 hit papers
194 papers, 13.8k citations indexed

About

David A. Boothman is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, David A. Boothman has authored 194 papers receiving a total of 13.8k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Molecular Biology, 77 papers in Oncology and 69 papers in Toxicology. Recurrent topics in David A. Boothman's work include Bioactive Compounds and Antitumor Agents (69 papers), Cancer therapeutics and mechanisms (61 papers) and DNA Repair Mechanisms (38 papers). David A. Boothman is often cited by papers focused on Bioactive Compounds and Antitumor Agents (69 papers), Cancer therapeutics and mechanisms (61 papers) and DNA Repair Mechanisms (38 papers). David A. Boothman collaborates with scholars based in United States, China and Greece. David A. Boothman's co-authors include Jinming Gao, Erik A. Bey, John J. Pink, Konstantin Leskov, Timothy J. Kinsella, Ying Dong, Hua Ai, Norased Nasongkla, Mark Meyers and Tracy Criswell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

David A. Boothman

192 papers receiving 13.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems

2006 1.0k citations Erik A. Bey, Jimin Ren et al. profile →
Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

2013 472 citations Julio C. Morales, Long-Shan Li et al. profile →
Klotho Inhibits Transforming Growth Factor-β1 (TGF-β1) Signaling and Suppresses Renal Fibrosis and Cancer Metastasis in Mice

2011 466 citations Yonglong Zou, David A. Boothman et al. profile →

Peers

Countries citing papers authored by David A. Boothman

Since Specialization

Citations

This map shows the geographic impact of David A. Boothman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Boothman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Boothman more than expected).

Fields of papers citing papers by David A. Boothman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Boothman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Boothman. The network helps show where David A. Boothman may publish in the future.

Co-authorship network of co-authors of David A. Boothman

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Boothman. A scholar is included among the top collaborators of David A. Boothman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Boothman. David A. Boothman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers 2019 ·Clinical Cancer Research ·Edward A. Motea, Xiumei Huang, (unknown), Jessica A. Kilgore, Noelle S. Williams, Xian‐Jin Xie, David E. Gerber, Muhammad Shaalan Beg, Erik A. Bey, David A. Boothman	33
2	Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding 2019 ·Molecular Cancer Therapeutics ·Saif Zaman, Xin Yu, (unknown), Adam R. Blanden, Yue Liu, (unknown), Bing Na, (unknown), John Gilleran, David A. Boothman, Stewart N. Loh, S. David Kimball, Darren R. Carpizo	25
3	Targeting NAD+ Metabolism to Enhance Radiation Therapy Responses 2019 ·PMC ·Joshua E. Lewis, (unknown), Reetta Holmila, Baran D. Sumer, Noelle S. Williams, Cristina M. Furdui, Melissa L. Kemp, David A. Boothman	2
4	Kub5-Hera RPRD1B Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers 2018 ·Clinical Cancer Research ·Edward A. Motea, Farjana Fattah, Ling Xiao, Luc Girard, Amy Rommel, Julio C. Morales, Praveen Patidar, Yunyun Zhou, Andrew C.G. Porter, Yang Xie, John D. Minna, David A. Boothman	12
5	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer 2016 ·Clinical Cancer Research ·(unknown), (unknown), Niranjan Venkateswaran, Margherita Melegari, Mariya Ilcheva, Julio C. Morales, Ferdinandos Skoulidis, John V. Heymach, David A. Boothman, Pier Paolo Scaglioni	64
6	NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer 2016 ·Molecular Cancer Therapeutics ·Long-Shan Li, (unknown), (unknown), Shuangping Liu, Hyunsil Park, Stephen G. Chun, William G. Bornmann, Joel Thibodeaux, Jingsheng Yan, Gaurab Chakrabarti, Xian-Jin Xie, Baran D. Sumer, David A. Boothman, John S. Yordy	45
7	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer 2015 ·Cancer Research ·Miao Wang, Mary Topalovski, Jason E. Toombs, Christopher M. Wright, Zachary Moore, David A. Boothman, Hiromi Yanagisawa, Huamin Wang, Agnieszka K. Witkiewicz, Diego H. Castrillón, Rolf A. Brekken	36
8	Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC 2015 ·Molecular Cancer Research ·Brian Madajewski, (unknown), Gaurab Chakrabarti, David A. Boothman, Erik A. Bey	50
9	The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells 2013 ·Clinical Cancer Research ·Kaijie Wu, Daxing Xie, Yonglong Zou, Tingting Zhang, Rey-Chen Pong, Guanghua Xiao, Ladan Fazli, Martin Gleave, Dalin He, David A. Boothman, Jer‐Tsong Hsieh	55
10	Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers 2013 ·Molecular Cancer Therapeutics ·Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Marie E. Varnes, Vernon Anderson, John J. Pink, Long Shan Li, Malina Patel, Lifen Cao, Zachary Moore, Amy Rommel, (unknown), Cheryl Lewis, David Euhus, William G. Bornmann, Donald J. Buchsbaum, Douglas R. Spitz, Jinming Gao, David A. Boothman	84
11	An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis 2012 ·Cancer Research ·Xiumei Huang, Ying Dong, Erik A. Bey, Jessica A. Kilgore, Joseph S. Bair, Long-Shan Li, Malina Patel, Elizabeth I. Parkinson, Yiguang Wang, Noelle S. Williams, Jinming Gao, Paul J. Hergenrother, David A. Boothman	119
12	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy 2011 ·Clinical Cancer Research ·Long Shan Li, Erik A. Bey, Ying Dong, Jieru Meng, Biswanath Patra, Jingsheng Yan, Xian‐Jin Xie, Rolf A. Brekken, Carlton C. Barnett, William G. Bornmann, Jinming Gao, David A. Boothman	94
13	Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation 2010 ·Cancer Research ·Ying Dong, Erik A. Bey, Long-Shan Li, Wareef Kabbani, Jingsheng Yan, Xian‐Jin Xie, Jer‐Tsong Hsieh, Jinming Gao, David A. Boothman	75
14	β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer Therapy 2010 ·Cancer Research ·Elvin Blanco, Erik A. Bey, Chalermchai Khemtong, (unknown), (unknown), Huabing Chen, Chase W. Kessinger, Kevin Carnevale, William G. Bornmann, David A. Boothman, Jinming Gao	115
15	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations 2009 ·Cancer Research ·Georgia Konstantinidou, Erik A. Bey, Andrea Rabellino, Katja Schuster, (unknown), Adi F. Gazdar, Augusto Amici, David A. Boothman, Pier Paolo Scaglioni	124
16	In vivo Off-Resonance Saturation Magnetic Resonance Imaging of αvβ3-Targeted Superparamagnetic Nanoparticles 2009 ·Cancer Research ·Chalermchai Khemtong, Chase W. Kessinger, Jimin Ren, Erik A. Bey, (unknown), Jagadeesh Setti Guthi, David A. Boothman, A. Dean Sherry, Jinming Gao	81
17	RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-κB–Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN 2009 ·Cancer Research ·Seong‐Mi Park, Dawen Zhao, Kimmo J. Hatanpaa, Bruce Mickey, Debabrata Saha, David A. Boothman, Michael D. Story, Eric T. Wong, Sandeep Burma, Maria‐Magdalena Georgescu, Vivek M. Rangnekar, (unknown), Amyn A. Habib	55
18	Intracellular Clusterin Inhibits Mitochondrial Apoptosis by Suppressing p53-Activating Stress Signals and Stabilizing the Cytosolic Ku70-Bax Protein Complex 2008 ·Clinical Cancer Research ·Ioannis P. Trougakos, Magda Lourda, Marianna H. Antonelou, Dimitris Kletsas, Vassilis G. Gorgoulis, Issidora S. Papassideri, Yonglong Zou, Lukas H. Margaritis, David A. Boothman, Efstathios S. Gonos	136
19	Nonhomologous End Joining Is Essential for Cellular Resistance to the Novel Antitumor Agent, β-Lapachone 2007 ·Cancer Research ·Melissa S. Bentle, Kathryn E. Reinicke, Ying Dong, Erik A. Bey, David A. Boothman	63
20	Regulation and Functions of Clusterin: A Protector Against Stress 2005 ·Acta medica Nagasakiensia ·Tracy Criswell, David A. Boothman	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact